BioMarin Pharmaceutical (BMRN) Price & Analysis

Compare

2,122 Followers

BMRN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$52.93 - $94.85

Previous CloseN/A

Volume465.01K

Average Volume (3M)2.32M

Market Cap

$10.37B

Enterprise Value$10.09B

Total Cash (Recent Filing)$1.27B

Total Debt (Recent Filing)$595.65M

Price to Earnings (P/E)20.3

Beta0.41

Next Earnings

Aug 05, 2025

EPS Estimate

0.83

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.95

Shares Outstanding191,775,670

10 Day Avg. Volume2,303,933

30 Day Avg. Volume2,321,781

Financial Highlights & Ratios

PEG Ratio0.90

Price to Book (P/B)1.81

Price to Sales (P/S)0.00

P/FCF Ratio17.01

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue0.91

Enterprise Value/Gross Profit4.36

Enterprise Value/Ebitda4.35

Forecast

1Y Price Target

$95.25

Price Target Upside75.93% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

BioMarin Pharmaceutical News

See All BMRN News

See All News >

Bulls Say, Bears Say

Bulls Say

Competitive AdvantageAscendis offers a potential competitive advantage with the option to co-formulate a growth hormone product with CNP.

Financial GuidanceBioMarin reaffirmed its previous financial guidance and plans to achieve a 40% non-GAAP operating margin.

Pipeline ExpansionThe acquisition of Inozyme Pharma is seen as a step in the right direction for BioMarin's pipeline expansion.

Bears Say

Benchmarking DifficultiesThe competitor's study did not include a monotherapy arm, making it challenging to benchmark data against historical growth velocity seen with monotherapy.

Clinical Data ChallengesThe data for the competitor's combination approach are still early, uncontrolled, and small in sample size, making it difficult to determine its future role in ACH treatment.

Earnings Call ConcernsConcerns that BMRN raised during their earnings call, namely durability of effects and potential of hGH-associated longer-term side effects, are still valid.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.54% Insiders

35.21% Mutual Funds

40.19% Other Institutional Investors

1.74% Public Companies and Individual Investors

Detailed Ownership Overview >

BMRN FAQ

What was BioMarin Pharmaceutical’s price range in the past 12 months?

BioMarin Pharmaceutical lowest stock price was $52.93 and its highest was $94.85 in the past 12 months.

What is BioMarin Pharmaceutical’s market cap?

BioMarin Pharmaceutical’s market cap is $10.37B.

When is BioMarin Pharmaceutical’s upcoming earnings report date?

BioMarin Pharmaceutical’s upcoming earnings report date is Aug 05, 2025 which is in 39 days.

How were BioMarin Pharmaceutical’s earnings last quarter?

BioMarin Pharmaceutical released its earnings results on May 01, 2025. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.682 by $0.268.

Is BioMarin Pharmaceutical overvalued?

According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BioMarin Pharmaceutical pay dividends?

BioMarin Pharmaceutical does not currently pay dividends.

What is BioMarin Pharmaceutical’s EPS estimate?

BioMarin Pharmaceutical’s EPS estimate is 0.83.

How many shares outstanding does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical has 191,775,670 shares outstanding.

What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?

BioMarin Pharmaceutical reported an EPS of $0.95 in its last earnings report, beating expectations of $0.682. Following the earnings report the stock price went down -1.084%.

Which hedge fund is a major shareholder of BioMarin Pharmaceutical?

Currently, no hedge funds are holding shares in BMRN

BioMarin Pharmaceutical Stock Smart Score

Neutral

Fundamentals

Return on Equity

9.64%

Trailing 12-Months

Asset Growth

3.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company that specializes in developing and commercializing innovative biopharmaceuticals for serious and life-threatening rare genetic diseases. Headquartered in San Rafael, California, BioMarin operates within the healthcare and biotechnology sectors, focusing on enzyme replacement therapies and gene therapies. Its core products include treatments for conditions such as phenylketonuria (PKU), mucopolysaccharidosis (MPS) disorders, and achondroplasia.

BMRN Company Deck

BMRN Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

BioMarin reported strong financial performance with notable revenue growth and profitability expansion, supported by successful pipeline progress. However, potential challenges include analyzing exposure to future pharmaceutical tariffs and managing VOXZOGO's revenue dynamics amid global order patterns. The overall sentiment leans towards optimism with strategic growth initiatives and robust financial results.Read More>

BMRN Revenue Breakdown

28.98% VIMIZIM

19.42% VOXZOGO

17.37% NAGLAZYME

12.56% PALYNZIQ

21.66% Other

BMRN Stock 12 Month Forecast

Average Price Target

$95.25

▲(75.93%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","121":"$121","72.25":"$72.3","88.5":"$88.5","104.75":"$104.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$95.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,72.25,88.5,104.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.05,61.89230769230769,66.73461538461538,71.57692307692308,76.41923076923077,81.26153846153846,86.10384615384615,90.94615384615385,95.78846153846155,100.63076923076923,105.47307692307692,110.31538461538462,115.15769230769232,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.05,59.988461538461536,62.926923076923075,65.86538461538461,68.80384615384615,71.74230769230769,74.68076923076923,77.61923076923077,80.5576923076923,83.49615384615385,86.43461538461538,89.37307692307692,92.31153846153846,{"y":95.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.05,58.04615384615384,59.04230769230769,60.03846153846153,61.034615384615385,62.03076923076923,63.026923076923076,64.02307692307693,65.01923076923077,66.01538461538462,67.01153846153846,68.00769230769231,69.00384615384615,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":75.07,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.13,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.21,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >